Disease-modifying trials in Alzheimer's disease: a European task force consensus. by Vellas, B, Andrieu, S, Sampaio, C, Wilcock, G

Endpoints for trials in Alzheimer's disease: a European task force consensus. by Vellas, B, Andrieu, S, Sampaio, C, Coley, N, Wilcock, G

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study by Pópulo H, Domingues B, Sampaio C, Lopes JM, Soares P

Get full text

Biomarkers for Alzheimer's disease therapeutic trials by Hampel, H, Wilcock, G, Andrieu, S, Aisen, P, Blennow, K, Broich, K, Carrillo, M, Fox, N, Frisoni, G, Isaac, M, Lovestone, S, Nordberg, A, Prvulovic, D, Sampaio, C, Scheltens, P, Weiner, M, Winblad, B, Coley, N, Vellas, B

Biomarkers for Alzheimer's disease therapeutic trials. by Hampel, H, Wilcock, G, Andrieu, S, Aisen, P, Blennow, K, Broich, K, Carrillo, M, Fox, N, Frisoni, G, Isaac, M, Lovestone, S, Nordberg, A, Prvulovic, D, Sampaio, C, Scheltens, P, Weiner, M, Winblad, B, Coley, N, Vellas, B

Methodological issues in primary prevention trials for neurodegenerative dementia. by Andrieu, S, Coley, N, Aisen, P, Carrillo, M, DeKosky, S, Durga, J, Fillit, H, Frisoni, G, Froelich, L, Gauthier, S, Jones, R, Jönsson, L, Khachaturian, Z, Morris, J, Orgogozo, J, Ousset, P, Robert, P, Salmon, E, Sampaio, C, Verhey, F, Wilcock, G, Vellas, B

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. by Vellas, B, Carrillo, M, Sampaio, C, Brashear, H, Siemers, E, Hampel, H, Schneider, L, Weiner, M, Doody, R, Khachaturian, Z, Cedarbaum, J, Grundman, M, Broich, K, Giacobini, E, Dubois, B, Sperling, R, Wilcock, G, Fox, N, Scheltens, P, Touchon, J, Hendrix, S, Andrieu, S, Aisen, P